Immunocore Holdings plc announced the achievement of target patient enrollment in its Phase 3 TEBE-AM clinical trial, which evaluated tebentafusp (KIMMTRAK) as monotherapy and in combination with pembrolizumab for HLA-A*02:01-positive patients with previously treated advanced melanoma. The trial enrolled 540 patients, and the primary endpoint is overall survival. Topline data from this registrational study is expected as early as the end of 2026. Immunocore Holdings plc operates in the biotechnology industry, developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases.

Immunocore Holdings plc reported second quarter 2026 financial results on August 6, 2026. Net product revenue from KIMMTRAK reached $115.9 million, an 18% increase year-over-year, driven by higher volumes in the United States and international regions. The company posted a net loss of $0.8 million ($0.02 per share) for the quarter, compared to a $10.3 million loss in Q2 2025. For the first half of 2026, Immunocore reported net income of $12.2 million ($0.23 per share). Cash and marketable securities totaled $880.2 million as of June 30, 2026. Clinically, enrollment in the Phase 3 TEBE-AM trial for advanced cutaneous melanoma is nearing its target of 540 patients, with data expected by late 2026. The company operates in the biotechnology industry, developing immunotherapies for cancer and other diseases.